The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment
Chien‐Hung Chen(Kaohsiung Chang Gung Memorial Hospital), Chuan–Mo Lee(Chang Gung University), Tsung‐Hui Hu(National Sun Yat-sen University), Sheng‐Nan Lu(Kaohsiung Chang Gung Memorial Hospital), Chi‐Sin Changchien(Kaohsiung Chang Gung Memorial Hospital), Chao‐Hung Hung(Kaohsiung Chang Gung Memorial Hospital), Jing‐Houng Wang(Kaohsiung Chang Gung Memorial Hospital)
Cited by 148
Related Papers
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Metabolic Factors and Risk of Hepatocellular Carcinoma by Chronic Hepatitis B/C Infection: A Follow-up Study in Taiwan
|Gastroenterology|2008|547
Hepatogastroenterology
|Hepatogastroenterology|2012|536